Evidence map›Paper›PMID 37197153›Full record

ArticlePhysics and imaging in radiation oncology2023

Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer.

Yasuo Yoshioka, Kazuma Sasamura, Makoto Ito, Masahiro Kaneko, Taro Takahashi, Wataru Anno, Nana Shimoyachi, Junji Suzuki, Takahito Okuda, Tairo Kashihara and 3 more

Open access · goldAbstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Yasuo YoshiokaDepartment of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazuma SasamuraDepartment of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Makoto ItoDepartment of Radiology, Aichi Medical University Hospital, Aichi, Japan.
Masahiro KanekoDepartment of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Taro TakahashiDepartment of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Wataru AnnoDepartment of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nana ShimoyachiDepartment of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Junji SuzukiRadiotherapy Quality Management Group, Toyota Memorial Hospital, Aichi, Japan.
Takahito OkudaDepartment of Radiation Oncology, Toyota Memorial Hospital, Aichi, Japan.
Tairo KashiharaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Koji InabaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Jun ItamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Japanese Foundation For Cancer Research · JPTokyo National Hospital · JPToyota Memorial Hospital · JPAichi Medical University Hospital · JPShinmatsudo Central General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Ultrahypofractionated radiation therapy is increasingly used in the treatment of prostate cancer. High-dose-rate brachytherapy (HDR-BT) and stereotactic body radiotherapy (SBRT) are representative methods of ultrahypofractionation. This study was performed to compare clinically applied treatment plans for patients who had been treated using HDR-BT vs. conventional or robotic SBRT. Materials and methods: Calculated dose-volume indices between HDR-BT without a perirectal spacer (n = 20), robotic SBRT without a spacer (n = 40), and conventional (non-robotic) SBRT with a spacer (n = 40) were compared. Percentages against the prescription dose regarding the planning target volume (PTV), bladder, rectum, and urethra were statistically compared. Results: The D50% of the PTV with HDR-BT (140.5% ± 4.9%) was significantly higher than that with robotic or conventional SBRT (116.2% ± 1.6%, 101.0% ± 0.4%, p < 0.01). The D2cm Conclusions: HDR-BT could administer a higher dose to the PTV and a lower dose to the bladder and rectum, at the cost of a slightly higher dose to the urethra compared with SBRT.

Indexed as

High-dose-rate brachytherapyMonotherapyProstate cancerStereotactic body radiation therapyUltrahypofractionation

Identifiers

PMID37197153
PMCPMC10183665
OpenAlexW4377010683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.